Bio/Pharma News

FDA Greenlights Orchard Therapeutics' Gene Therapy for Children's MLD; AGC Biologics Selected for Manufacturing

March 20, 2024

FDA's approval makes Orchard Therapeutics' Lenmeldy (atidarsagene autotemcel) the first gene therapy approved to treat pediatric metachromatic leukodystrophy in the US.

Mapp Biopharmaceutical Teams Up with ProBioGen and to Develop Antibody Against Marburg Virus Disease

March 16, 2024

Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection

Chime Biologics to Manufacture Novel Antibody Cancer Immunotherapy for Domain Therapeutics

March 14, 2024

In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.

Cellares Set to Launch Good Manufacturing Practice–Compliant Cell Shuttle Manufacturing Platform

March 12, 2024

The Cell Shuttle platform will manufacture cell therapies for its first clinical trials by the end of the year.

EMA Validates Parallel Applications for Datopotamab Deruxtecan in Two Types of Cancer

March 08, 2024

EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.

J&J Completes $2 Billion Ambrx Acquisition, Boosts Pipeline for Next-Gen ADCs

March 07, 2024

Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.

Cellares Innovates With Automated Cell and Gene Therapy Platform

March 07, 2024

Cellares CEO Fabian Gerlinghaus shares how an automated, closed-production platform with a small footprint can dramatically impact cost savings and scalability for cell and gene therapies.

AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation

March 06, 2024

Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.

Nona Biosciences Partners with Boostimmune on ADC Development

February 28, 2024

Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.

AstraZeneca Completes Acquisition of Icosavax

February 21, 2024

AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.